HUTCHMED (China) Limited - HCM STOCK NEWS

IMPACT

SENTIMENT

11/30/2023 07:00 PM

HCM : Nasdaq

HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses

IMPACT

SENTIMENT

11/08/2023 07:11 PM

HCM : Nasdaq

HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

IMPACT

SENTIMENT

09/29/2023 04:30 AM

HCM : Nasdaq

HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

IMPACT

SENTIMENT

09/12/2023 04:30 AM

HCM : Nasdaq

HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

IMPACT

SENTIMENT

09/11/2023 08:00 PM

HCM : Nasdaq

HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

IMPACT

SENTIMENT

08/28/2023 08:00 PM

HCM : Nasdaq

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

IMPACT

SENTIMENT

08/20/2023 08:00 PM

HCM : Nasdaq

HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China

IMPACT

SENTIMENT

07/31/2023 07:41 AM

HCM : Nasdaq

HUTCHMED Reports 2023 Interim Results and Provides Business Updates

IMPACT

SENTIMENT

07/19/2023 08:00 PM

HCM : Nasdaq

HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

IMPACT

SENTIMENT

07/13/2023 04:30 AM

HCM : Nasdaq

HUTCHMED Announces Changes to Board of Directors and Technical Committee

HUTCHMED (China) Limited

Nasdaq:HCM

HCM Rankings

#1868 Ranked by Market Cap

N/A Ranked by Dividends

HCM Stock Data

Industry Pharmaceutical Preparation Manufacturing

Sector Manufacturing

Website Link

Country HK

City Central

About HCM

HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs.